Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Usha Chandrahasa

Allergy & Immunology Port Charlotte, FL Medical Doctor

NPI 1548254857 CMS profile 341683

3400 Tamiami Trl, Ste 201, Port Charlotte, FL 33952

Open in the dashboard

General payments

$105,503

299 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Usha Chandrahasa of Port Charlotte, FL is reported in the CMS Open Payments database as having received $105,503 across 299 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $602 26
2024 General $18,950 23
2023 General $29,593 68
2022 General $7,185 41
2021 General $11,650 24
2020 General $6,471 7
2019 General $31,051 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Usha Chandrahasa
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Usha Chandrahasa were reported at $602. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Usha Chandrahasa Allergy & Immunology median Middle half National median
2019 $31,051 $594 $163–$1,512 $163
2020 $6,471 $426 $106–$1,233 $114
2021 $11,650 $638 $157–$1,708 $132
2022 $7,185 $790 $205–$1,961 $149
2023 $29,593 $852 $220–$2,147 $160
2024 $18,950 $865 $203–$2,267 $164
2025 $602 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $63,855 67 payments
  2. Shire North American Group Inc $17,780 31 payments
  3. Genentech USA, Inc. $15,274 35 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $3,281 12 payments
  5. Genzyme Corporation $1,592 19 payments
  6. AstraZeneca Pharmaceuticals LP $895 30 payments
  7. GlaxoSmithKline, LLC. $618 28 payments
  8. CSL Behring $556 20 payments
  9. Regeneron Healthcare Solutions, Inc. $312 10 payments
  10. Pharming Healthcare, Inc. $194 6 payments
  11. Other $1,147 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $77,679 27 payments
  2. Travel and Lodging $15,939 27 payments
  3. Food and Beverage $8,043 231 payments
  4. Consulting Fee $3,621 6 payments
  5. Education $221 8 payments
Products named General payments · program years 2019–2025
  1. CUVITRU $40,047 55 payments
  2. HYQVIA $24,318 28 payments
  3. Xolair $15,000 33 payments
  4. DUPIXENT Immunology $1,804 24 payments
  5. Hizentra $451 16 payments
  6. TEZSPIRE $358 10 payments
  7. TRELEGY ELLIPTA $321 23 payments
  8. DUPIXENT Inflammation And Immunology $281 8 payments
  9. RUCONEST $194 6 payments
  10. AREXVY $125 1 payment
  11. Other $1,747 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

4,972

Median for Allergy/ Immunology: 449

Drug cost

$979,564

Median for Allergy/ Immunology: $169,700

Branded share of claims

29%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 153 $155,008
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 13 $117,318
Advair Hfa Fluticasone Propion/Salmeterol Brand 244 $112,062
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 111 $104,274
Dupixent Syringe Dupilumab Brand 23 $85,859
Spiriva Respimat Tiotropium Bromide Brand 76 $69,163
Breo Ellipta Fluticasone/Vilanterol Brand 115 $63,711
Symbicort Budesonide/Formoterol Fumarate Brand 119 $45,527
Dulera Mometasone/Formoterol Brand 63 $35,473
Arnuity Ellipta Fluticasone Furoate Brand 104 $32,307

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$404,741

Of which drugs: $251,089

Medicare patients

797

Average age 74

Services billed

15,327

519 women, 278 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
COPD 50%
Ischemic heart disease 37%
Depression 34%
Chronic kidney disease 30%
Diabetes 23%
Osteoporosis 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 13 13 $1,700

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $1,389
$1,389 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $114
$114 13 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $106
$106 — —
Xolair
  • Genentech USA, Inc. $26
$26 — —
DUPIXENT
  • GENZYME CORPORATION $24
$24 23 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

299 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record